Evidence suggests that endocannabinoids might suppress cancer cell viability through the activation of classic cannabinoid receptors such as cannabinoid receptor-1/2 (CB1 and CB2) and vanilloid receptor-1 (VR1). Here, TRPV1 is linked to cancer.